https://www.selleckchem.com/pr....oducts/baricitinib-l
Ovarian cancer (OC) is an aggressive disease, primarily diagnosed in late stages with only 20% of patients surviving more than 5 years after diagnosis. There is a pending need to improve current diagnostics and prognostics. In this study, we investigated total circulating cell-free microRNA (cf-miRNA) levels as well as a panel of cf-miRNAs in the plasma of OC patients (n = 10, patients with benign lesions (n = 45) and healthy controls (n = 99). High levels of cf-miRNAs correlated with unfavourable clinical features and w
Like
Comment
Share
